Report cover image

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Publisher Global Markets Direct
Published Jun 30, 2022
Length 375 Pages
SKU # GMD17341285

Description

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2022, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 12, 23, 9 and 1 respectively.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

375 Pages
Introduction
Global Markets Direct Report Coverage
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Overview
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Companies Involved in Therapeutics Development
AbbVie Inc
Acceleron Pharma Inc
Actuate Therapeutics Inc
Bristol-Myers Squibb Co
Chengdu Zenitar Biomedical Technology Co Ltd
CTI BioPharma Corp
Disc Medicine Inc
F. Hoffmann-La Roche Ltd
Galecto Inc
Geron Corp
Hangzhou East China Pharmaceutical Group Co Ltd
Imago BioSciences Inc
Incyte Corp
iOnctura SA
Italfarmaco SpA
JW Pharmaceutical Corp
Kartos Therapeutics Inc
Karyopharm Therapeutics Inc
Lynk Pharmaceutical Hangzhou Co Ltd
MEI Pharma Inc
Merck & Co Inc
Millennium Pharmaceuticals Inc
MorphoSys AG
Novartis AG
NS Pharma Inc
Pharmaxis Ltd
Rhizen Pharmaceuticals SA
Samus Therapeutics Inc
Sierra Oncology Inc
Sino Biopharmaceutical Ltd
Sumitomo Dainippon Pharma Oncology, Inc
Suzhou Zelgen Biopharmaceutical Co Ltd
Telios Pharma Inc
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drug Profiles
ABBV-744 – Drug Profile
AVID-200 – Drug Profile
BMS-986158 – Drug Profile
bomedemstat tosylate – Drug Profile
crizanlizumab – Drug Profile
CWP-291 – Drug Profile
DISC-0974 – Drug Profile
elraglusib – Drug Profile
fedratinib – Drug Profile
filgotinib maleate – Drug Profile
GB-2064 – Drug Profile
givinostat – Drug Profile
HDM-201 – Drug Profile
ilginatinib – Drug Profile
imetelstat sodium – Drug Profile
INCB-00928 – Drug Profile
INCB-57643 – Drug Profile
IOA-244 – Drug Profile
itacitinib adipate – Drug Profile
jaktinib hydrochloride – Drug Profile
LCL-161 – Drug Profile
LNK-01002 – Drug Profile
luspatercept – Drug Profile
mivebresib – Drug Profile
momelotinib dihydrochloride – Drug Profile
navitoclax dihydrochloride – Drug Profile
navtemadlin – Drug Profile
NIS-793 – Drug Profile
OB-756 – Drug Profile
pacritinib – Drug Profile
parsaclisib – Drug Profile
pelabresib – Drug Profile
pembrolizumab – Drug Profile
pevonedistat hydrochloride – Drug Profile
pracinostat – Drug Profile
PUH-71 – Drug Profile
PXS-5505A – Drug Profile
RG-6354 – Drug Profile
ruxolitinib phosphate – Drug Profile
sabatolimab – Drug Profile
selinexor – Drug Profile
TL-895 – Drug Profile
TP-3654 – Drug Profile
TQ-05105 – Drug Profile
umbralisib tosylate – Drug Profile
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Dormant Projects
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Discontinued Products
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Product Development Milestones
Featured News & Press Releases
Dec 11, 2020: Bristol Myers Squibb receives positive CHMP opinion for Inrebic (fedratinib) for adult patients with newly diagnosed and previously treated myelofibrosis
Jun 07, 2019: FDA grants fast-track designation to bone marrow cancer drug
Jan 02, 2019: CTI BioPharma completes enrolment in myelofibrosis drug trial
Dec 18, 2018: CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis
Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting
Nov 30, 2015: Incyte’s Jakafi to be Featured in over 60 Abstracts at ASH Annual Meeting
Dec 07, 2012: Incyte Announces Presentation Of New Data For Jakafi At 2012 American Society Of Hematology Annual Meeting
Aug 28, 2012: Incyte's Partner Novartis Receives European Approval For Jakavi
Jun 04, 2012: Incyte Presents New Clinical Data Of Jakafi At ASCO 2012 Annual Meeting
May 16, 2012: Sanofi To Present Data On SAR302503 At 2012 American Society Of Clinical Oncology Annual Meeting
Apr 20, 2012: Incyte Announces EU Regulatory Milestone From Novartis For Ruxolitinib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022 (Contd..1)
Table 6: Products under Development by Companies, 2022 (Contd..2)
Table 7: Number of Products by Stage and Target, 2022
Table 8: Number of Products by Stage and Target, 2022 (Contd..1)
Table 9: Number of Products by Stage and Mechanism of Action, 2022
Table 10: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Table 11: Number of Products by Stage and Route of Administration, 2022
Table 12: Number of Products by Stage and Molecule Type, 2022
Table 13: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by AbbVie Inc, 2022
Table 14: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Acceleron Pharma Inc, 2022
Table 15: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Actuate Therapeutics Inc, 2022
Table 16: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Bristol-Myers Squibb Co, 2022
Table 17: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Chengdu Zenitar Biomedical Technology Co Ltd, 2022
Table 18: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by CTI BioPharma Corp, 2022
Table 19: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Disc Medicine Inc, 2022
Table 20: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by F. Hoffmann-La Roche Ltd, 2022
Table 21: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Galecto Inc, 2022
Table 22: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Geron Corp, 2022
Table 23: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022
Table 24: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Imago BioSciences Inc, 2022
Table 25: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Incyte Corp, 2022
Table 26: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by iOnctura SA, 2022
Table 27: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Italfarmaco SpA, 2022
Table 28: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by JW Pharmaceutical Corp, 2022
Table 29: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Kartos Therapeutics Inc, 2022
Table 30: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Karyopharm Therapeutics Inc, 2022
Table 31: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022
Table 32: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by MEI Pharma Inc, 2022
Table 33: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Merck & Co Inc, 2022
Table 34: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Millennium Pharmaceuticals Inc, 2022
Table 35: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by MorphoSys AG, 2022
Table 36: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Novartis AG, 2022
Table 37: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by NS Pharma Inc, 2022
Table 38: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Pharmaxis Ltd, 2022
Table 39: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Rhizen Pharmaceuticals SA, 2022
Table 40: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Samus Therapeutics Inc, 2022
Table 41: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Sierra Oncology Inc, 2022
Table 42: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Sino Biopharmaceutical Ltd, 2022
Table 43: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Sumitomo Dainippon Pharma Oncology, Inc, 2022
Table 44: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Table 45: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Pipeline by Telios Pharma Inc, 2022
Table 46: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Dormant Projects, 2022
Table 47: Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Targets, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us